{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T19:14:42Z","timestamp":1793387682980,"version":"4.5.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T00:00:00Z","timestamp":1609977600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T00:00:00Z","timestamp":1609977600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Osteoporos Rep"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1007\/s11914-020-00652-w","type":"journal-article","created":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T01:33:11Z","timestamp":1609983191000},"page":"15-22","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":77,"title":["Romosozumab: a Review of Efficacy, Safety, and Cardiovascular Risk"],"prefix":"10.1007","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5857-0629","authenticated-orcid":false,"given":"Cy","family":"Fixen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Tunoa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,7]]},"reference":[{"key":"652_CR1","unstructured":"Teriparatide [package insert]. Indianapolis, IN: Eli Lilly and Company; 2002."},{"key":"652_CR2","unstructured":"Abaloparatide [package insert]. Waltham, MA: Radius Health, Inc; 2017."},{"key":"652_CR3","unstructured":"Romosozumab [package insert]. Thousand Oaks, CA: Amgen, Inc; 2019."},{"key":"652_CR4","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.bone.2016.11.024","volume":"96","author":"MM Weivoda","year":"2017","unstructured":"Weivoda MM, Youssef SJ, Oursler MJ. Sclerostin expression and functions beyond the osteocyte. Bone. 2017;96:45\u201350. https:\/\/doi.org\/10.1016\/j.bone.2016.11.024.","journal-title":"Bone."},{"issue":"5","key":"652_CR5","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1093\/hmg\/10.5.537","volume":"10","author":"W Balemans","year":"2001","unstructured":"Balemans W, Ebeling M, Patel N, van Hul E, Olson P, Dioszegi M, et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet. 2001;10(5):537\u201343. https:\/\/doi.org\/10.1093\/hmg\/10.5.537.","journal-title":"Hum Mol Genet"},{"issue":"3","key":"652_CR6","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1086\/318811","volume":"68","author":"ME Brunkow","year":"2001","unstructured":"Brunkow ME, Gardner JC, Van Ness J, et al. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet. 2001;68(3):577\u201389. https:\/\/doi.org\/10.1086\/318811.","journal-title":"Am J Hum Genet"},{"issue":"16","key":"652_CR7","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","volume":"375","author":"F Cosman","year":"2016","unstructured":"\u2022\u2022 Cosman F, Crittenden DB, Adachi JD, et al. Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med. 2016;375(16):1532\u201343. https:\/\/doi.org\/10.1056\/NEJMoa1607948.","journal-title":"N Engl J Med"},{"issue":"15","key":"652_CR8","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","volume":"377","author":"KG Saag","year":"2017","unstructured":"\u2022\u2022 Saag KG, Petersen J, Brandi ML, et al. Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med. 2017;377(15):1417\u201327. https:\/\/doi.org\/10.1056\/NEJMoa1708322.","journal-title":"N Engl J Med"},{"issue":"9","key":"652_CR9","doi-asserted-by":"publisher","first-page":"3183","DOI":"10.1210\/jc.2017-02163","volume":"103","author":"EM Lewiecki","year":"2018","unstructured":"\u2022\u2022 Lewiecki EM, Blicharski T, Goemaere S, et al. A phase III randomized placebo-controlled trial to evaluate efficacy and safety of romosozumab in men with osteoporosis. J Clin Endocrinol Metab. 2018;103(9):3183\u201393. https:\/\/doi.org\/10.1210\/jc.2017-02163.","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"652_CR10","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1002\/jbmr.3439","volume":"33","author":"F Cosman","year":"2018","unstructured":"Cosman F, Crittenden DB, Ferrari S, Lewiecki EM, Jaller-Raad J, Zerbini C, et al. Romosozumab FRAME study: a post hoc analysis of the role of regional background fracture risk on nonvertebral fracture outcome. J Bone Miner Res. 2018;33(8):1407\u201316. https:\/\/doi.org\/10.1002\/jbmr.3439.","journal-title":"J Bone Miner Res"},{"key":"652_CR11","unstructured":"\u2022 Amgen, Inc. BLA 761062 Romosozumab: U. S. Food and Drug Administration\/Center for Drug Evaluation and Research; Division of Bone, Reproductive, and Urologic Products: FDA Briefing document. Amgen, Inc. Jan 16, 2019. https:\/\/www.fda.gov\/media\/121257\/download (accessed 2020 May 04)."},{"key":"652_CR12","unstructured":"\u2022 Amgen, Inc. BLA 761062 Romosozumab: U. S. Food and Drug Administration\/Center for Drug Evaluation and Research; Division of Bone, Reproductive, and Urologic Products Office of Drug Evaluation III Multidisciplinary Review and Evaluation document. Amgen, Inc. July 9, 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/761062Orig1s000MultidisciplineR.pdf (accessed 2020 May 01)."},{"issue":"7","key":"652_CR13","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1001\/jama.2016.11136","volume":"316","author":"PD Miller","year":"2016","unstructured":"Miller PD, Hattersley G, Riis BJ, Williams GC, Lau E, Russo LA, et al. Effect of Abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial [published correction appears in JAMA. 2017 Jan 24;317(4):442]. JAMA. 2016;316(7):722\u201333. https:\/\/doi.org\/10.1001\/jama.2016.11136.","journal-title":"JAMA."},{"issue":"18","key":"652_CR14","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa067312","volume":"356","author":"DM Black","year":"2007","unstructured":"Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356(18):1809\u201322. https:\/\/doi.org\/10.1056\/NEJMoa067312.","journal-title":"N Engl J Med"},{"issue":"5","key":"652_CR15","doi-asserted-by":"publisher","first-page":"e19595","DOI":"10.1371\/journal.pone.0019595","volume":"6","author":"D Zhu","year":"2011","unstructured":"Zhu D, Mackenzie NC, Mill\u00e1n JL, Farquharson C, MacRae VE. The appearance and modulation of osteocyte marker expression during calcification of vascular smooth muscle cells. PLoS One. 2011;6(5):e19595. https:\/\/doi.org\/10.1371\/journal.pone.0019595.","journal-title":"PLoS One"},{"key":"652_CR16","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.bone.2016.10.010","volume":"96","author":"AH van Lierop","year":"2017","unstructured":"van Lierop AH, Appelman-Dijkstra NM, Papapoulos SE. Sclerostin deficiency in humans. Bone. 2017;96:51\u201362. https:\/\/doi.org\/10.1016\/j.bone.2016.10.010.","journal-title":"Bone."},{"issue":"1","key":"652_CR17","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s00198-012-2213-5","volume":"24","author":"JH Kang","year":"2013","unstructured":"Kang JH, Keller JJ, Lin HC. Bisphosphonates reduced the risk of acute myocardial infarction: a 2-year follow-up study. Osteoporos Int. 2013;24(1):271\u20137. https:\/\/doi.org\/10.1007\/s00198-012-2213-5.","journal-title":"Osteoporos Int"},{"issue":"8","key":"652_CR18","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1002\/jbmr.3448","volume":"33","author":"CW Sing","year":"2018","unstructured":"Sing CW, Wong AY, Kiel DP, et al. Association of alendronate and risk of cardiovascular events in patients with hip fracture. J Bone Miner Res. 2018;33(8):1422\u201334. https:\/\/doi.org\/10.1002\/jbmr.3448.","journal-title":"J Bone Miner Res"},{"issue":"4","key":"652_CR19","doi-asserted-by":"publisher","first-page":"e0122646","DOI":"10.1371\/journal.pone.0122646","volume":"10","author":"DH Kim","year":"2015","unstructured":"Kim DH, Rogers JR, Fulchino LA, Kim CA, Solomon DH, Kim SC. Bisphosphonates and risk of cardiovascular events: a meta-analysis. PLoS One. 2015;10(4):e0122646. Published 2015 Apr 17. https:\/\/doi.org\/10.1371\/journal.pone.0122646.","journal-title":"PLoS One"},{"key":"652_CR20","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.atherosclerosis.2016.06.039","volume":"252","author":"G Kranenburg","year":"2016","unstructured":"Kranenburg G, Bartstra JW, Weijmans M, de Jong PA, Mali WP, Verhaar HJ, et al. Bisphosphonates for cardiovascular risk reduction: a systematic review and meta-analysis. Atherosclerosis. 2016;252:106\u201315. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2016.06.039.","journal-title":"Atherosclerosis."}],"container-title":["Current Osteoporosis Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11914-020-00652-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11914-020-00652-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11914-020-00652-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,5]],"date-time":"2021-03-05T05:28:35Z","timestamp":1614922115000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11914-020-00652-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,7]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["652"],"URL":"https:\/\/doi.org\/10.1007\/s11914-020-00652-w","relation":{},"ISSN":["1544-1873","1544-2241"],"issn-type":[{"value":"1544-1873","type":"print"},{"value":"1544-2241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,7]]},"assertion":[{"value":"18 December 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"None of the authors have conflict(s) of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}